Elite in Neuroendocrine Tumor

Markus Raderer

Vienna, AT 
Elite in Neuroendocrine Tumor
Vienna, AT 
OverviewLocationsClinical Research

Overview

Markus Raderer practices in Vienna, Austria. Dr. Raderer is rated as an Elite expert by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are B-Cell Lymphoma, Neuroendocrine Tumor, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma, and Splenectomy.

His clinical research consists of co-authoring 209 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 38 articles in the study of Neuroendocrine Tumor.

Gender
Male

Locations

Vienna, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL)
Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL)
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2025
Intervention Type: Drug
Study Drugs: Tafasitamab, Acalabrutinib
Study Phase: Phase 2
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

209 Total Publications

KV11.1 (hERG1)-centered macromolecular membrane complexes regulate proliferation in B cell lymphomas and constitute novel pharmacological targets.
KV11.1 (hERG1)-centered macromolecular membrane complexes regulate proliferation in B cell lymphomas and constitute novel pharmacological targets.
Journal: Pharmacological research
Published: July 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Raderer's expertise for a condition
ConditionClose
View All 35 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile